erdosteine

Also Known As:

(+-)-((((tetrahydro-2-oxo-3-thienyl)carbamoyl)methyl)thio)acetic acid; Dostein; Edirel; Esteclin; RV 144; RV-144; S-(2-(N-3-(2-oxo-tetrahydrothienyl)acetamido))thioglycolic acid; Vectrine

Networked: 118 relevant articles (31 outcomes, 51 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - Thioglycolates: 2
        erdosteine: 118
- Sulfur Compounds: 278
  - Sulfhydryl Compounds: 4168
    - Thioglycolates: 2
      - erdosteine: 118
  - Thiophenes: 257
    - erdosteine: 118
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - erdosteine: 118

Experts

1.	Iraz, Mustafa: 8 articles (02/2009 - 02/2003)
2.	Akyol, Omer: 6 articles (02/2009 - 02/2003)
3.	Yilmaz, H Ramazan: 6 articles (04/2008 - 07/2004)
4.	Yildirim, Zeki: 6 articles (01/2005 - 02/2003)
5.	Cazzola, Mario: 5 articles (01/2021 - 01/2018)
6.	Page, Clive: 5 articles (11/2020 - 10/2017)
7.	Uz, Efkan: 5 articles (01/2015 - 11/2005)
8.	Sogut, Sadik: 5 articles (12/2005 - 02/2003)
9.	Matera, Maria Gabriella: 4 articles (01/2021 - 01/2018)
10.	Rogliani, Paola: 4 articles (01/2021 - 01/2018)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 03/01/2009 - "Erdosteine could be most beneficial in patients who have repeated, prolonged or severe exacerbations of COPD." 08/01/2015 - "Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial." 04/01/2010 - "to test the available evidence for the efficacy of erdosteine in adults with stable or exacerbated CB/COPD. " 07/31/2023 - "However, such studies have demonstrated that NAC and S-CMC reduced the exacerbation risk only in patients not treated with ICS, whereas erdosteine reduced COPD exacerbations irrespective of concomitant ICS use suggesting that erdosteine has additional pharmacological actions to ICS. " 10/01/2017 - "Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study."
2.	Reperfusion Injury 10/01/2017 - "To investigate the potential protective effects of erdosteine against the harmful effects of ischemia-reperfusion injury on the liver in an experimental rat model. " 10/01/2017 - "Erdosteine ameliorates the harmful effects of ischemia-reperfusion injury on the liver of rats." 10/01/2004 - "Erdosteine ameliorates neurological outcome and oxidative stress due to ischemia/reperfusion injury in rabbit spinal cord." 10/01/2017 - "The current study is the first to have shown the favorable effects of erdosteine on the harmful effects of experimental hepatic ischemia-reperfusion injury." 01/01/2010 - "The aim of the present study was to investigate the effect of erdosteine on renal reperfusion injury. "
3.	Ischemia 02/23/2018 - "We also found that erdosteine had beneficial effects by reversing undesirable effects of ischemia/reperfusion. " 02/23/2018 - "Relative resistance, a marker of erythrocyte deformability, was increased significantly by ischemia/reperfusion compared to the control and ischemia/reperfusion - erdosteine groups (P < 0.05). " 02/23/2018 - "The values of the ischemia/reperfusion group were significantly higher than those of the control and ischemia/reperfusion - erdosteine groups (P < 0.0001 and P = 0.024, respectively). " 02/23/2018 - "Results: Comparisons of the control and ischemia/reperfusion - erdosteine groups revealed similar results (P = 0.051). " 02/23/2018 - "Rats were divided into 3 groups: a randomized control group (group 'control', n = 6), an ischemia/reperfusion group without erdosteine (group 'ischemia/reperfusion', n = 6), and an ischemia/reperfusion group with erdosteine at 150 mg kg−1, intraperitoneally (group 'ischemia/reperfusion - erdosteine', n = 6). "
4.	Bronchitis 04/01/2010 - "The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data." 11/01/1995 - "Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study)." 12/01/1996 - "Erdosteine is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. " 01/01/2008 - "The substantial antitussive effects of erdosteine were first documented in clinical trials even though mucolytic agents are regarded as not consistently effective in ameliorating cough in patients with bronchitis, although they may be of benefit to this population in other ways. " 07/01/1993 - "Although hypertonic saline aerosol and erdosteine in patients with bronchitis, and amiloride aerosol in patients with cystic fibrosis have been shown to improve mucus clearance, their clinical utility has not been adequately studied."
5.	Chronic Bronchitis 09/01/1999 - "[Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion]." 01/01/1991 - "Sixteen former smokers affected by chronic bronchitis, preselected for their mucociliary responsiveness to an inhaled beta 2-agonist, were divided into two groups (matched by number, sex, age and FEV1%) and orally treated with placebo or erdosteine (300 mg t.i.d.) for 8 days. " 01/01/1991 - "Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis." 01/01/2018 - "Our findings included data from ten studies involving 1278 patients and show that erdosteine is able to improve the clinical score of patients with chronic bronchitis and COPD, and also reduces the overall risk of chronic bronchitis/COPD exacerbations, and reduces the risk of experiencing at least one exacerbation. " 03/01/2009 - "To review the experimental and clinical trials on erdosteine in COPD and chronic bronchitis. "

Related Drugs and Biologics

1.	Antioxidants
2.	Cisplatin (Platino)
3.	Acetylcysteine (Siran)
4.	Vitamins
5.	Free Radical Scavengers
6.	Expectorants (Mucolytics)
7.	Amoxicillin (Wymox)
8.	Carbocysteine (S-Carboxymethylcysteine)
9.	Proteins (Proteins, Gene)
10.	Antitussive Agents (Antitussives)

Related Therapies and Procedures

1.	Intratympanic Injection
2.	Therapeutics
3.	Polypharmacy
4.	Duration of Therapy